血脂异常
医学
冠状动脉疾病
血脂谱
临床试验
疾病
内科学
心脏病学
冲程(发动机)
急性冠脉综合征
风险因素
重症监护医学
临床终点
心血管健康
冠心病
代理终结点
动脉疾病
血管疾病
药物开发
终点测定
冠心病
风险评估
动脉粥样硬化性心血管疾病
作者
Peter E Thomas,Signe Vedel‐Krogh,Florian Kronenberg,Børge Grønne Nordestgaard
出处
期刊:PubMed
[National Institutes of Health]
日期:2026-11-13
标识
DOI:10.1093/clinchem/hvag154
摘要
BACKGROUND: Lipoprotein(a) [Lp(a)] is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD = myocardial infarction, ischemic stroke, peripheral artery disease) and aortic valve stenosis. Plasma concentrations of Lp(a) are >90% genetically determined. Multiple drugs in development reduce lipoprotein(a) by 80% to 98%. While the recently announced topline results, the phase 3 Lp(a)HORIZON trial of pelacarsen did not meet its primary cardiovascular endpoint despite lowering Lp(a), and 3 other cardiovascular outcomes trials remain ongoing. Lipoprotein(a) testing is currently increasing rapidly in many countries. CONTENT: Most guidelines on dyslipidemia and prevention of cardiovascular disease worldwide now advise that Lp(a) should be measured once in all adults, ideally jointly with the first lipid profile ordered. If previous lipid profiles were taken, then Lp(a) should be included in the next lipid profile. Lipoprotein(a) should ideally be measured in nmol/L, and repeat measurements are relevant if drugs are given to lower Lp(a) concentrations, initially at suspected acute coronary syndrome or stroke and again after 1 month, and sometimes in women after menopause. Measuring Lp(a) levels alongside a standard lipid profile provides a more comprehensive initial assessment of a patient's overall cardiovascular risk. Clinical chemistry laboratories that measure lipid profiles should therefore also offer Lp(a) testing. This is easily done as Lp(a) assays can be run on most major clinical chemistry platforms. High Lp(a) is >105 nmol/L (>50 mg/dL). SUMMARY: As use of Lp(a) testing is increasing rapidly worldwide, more clinical chemistry laboratories will likely offer this test locally. Measuring Lp(a) levels alongside a standard lipid profile provides a more comprehensive initial lipid assessment of a patient's cardiovascular risk.
科研通智能强力驱动
Strongly Powered by AbleSci AI